Testing for BRAF fusions in patients with advanced BRAF/NRAS/KIT wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy - Le Flahec, Glen; Briolais, Manon; Guibourg, Briac; Lemasson, Gilles; Grippari, Jean-Luc; Ledé, Francoise; Marcorelles, Pascale; Uguen, Arnaud (Journal of clinical pathology, 2020)
Keywords: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Apoptosis; Biomarkers, Tumor - genetics; Brain cancer; Female; fluorescent; Gene Fusion; GTP Phosphohydrolases - genetics; Humans; hybridization; Immunotherapy; In Situ Hybridization, Fluorescence; Male; Melanoma; Melanoma - drug therapy; Melanoma - enzymology; Melanoma - genetics; Membrane Proteins - genetics; Metastasis; Middle Aged; Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors; Mitogen-Activated Protein Kinase Kinases - metabolism; Molecular Targeted Therapy; Mutation; Patient Selection; Patients; Precision Medicine; Predictive Value of Tests; Protein Kinase Inhibitors - therapeutic use; Proto-Oncogene Proteins B-raf - genetics; Proto-Oncogene Proteins c-kit - genetics; Short report; Skin Neoplasms - drug therapy; Skin Neoplasms - enzymology; Skin Neoplasms - genetics; Tumors; Germany; melanoma; fluorescentin situhybridization; BRAF; gene fusion